HypertensionPhase 3NCT06952530
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
A Phase 3 study testing Orforglipron in people with Hypertension, run by Eli Lilly and Company at 99 sites in 11 countries.
Trial summary
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- Orforglipron
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 487 participants
- Where
- 99 sitesin 11 countries
- Study dates
- 30 Apr 2025to Sep 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- refer to the GZPL master protocol study for screening eligibility.
Who cannot join
- refer to the GZPL master protocol study for screening eligibility.
Trial locations and contacts
99 sites in 11 countries.
99 sites in 11 countries
United States28 sites
Sinai Hospital Of Baltimore
Baltimore, Maryland, 21209
Ascension Saint Agnes Heart Care
Baltimore, Maryland, 21229
Excel Medical Clinical Trials
Boca Raton, Florida, 33434
Care Access - Brandon
Brandon, Florida, 33510
StudyMetrix Research
City of Saint Peters, Missouri, 63303
Remington-Davis, Inc
Columbus, Ohio, 43215
Valley Clinical Trials, Inc.
Covina, California, 91723
Dallas Heart and Vascular Consultants, PA
Duncanville, Texas, 75137
East-West Medical Research Institute
Honolulu, Hawaii, 96814
Northeast Research Institute - Downtown Office
Jacksonville, Florida, 32204
Excel Clinical Research, LLC
Las Vegas, Nevada, 89109
Palm Research Center Sunset
Las Vegas, Nevada, 89148
Carient Heart & Vascular - Manassas
Manassas, Virginia, 20109
Care Access - Mauldin
Mauldin, South Carolina, 29662
Texas Institute of Cardiology, PA
McKinney, Texas, 75071
Lucida Clinical Trials
New Bedford, Massachusetts, 02740
Health Research of Hampton Roads, Inc.
Newport News, Virginia, 23606
North Hills Family Medicine/North Hills Medical Research
North Richland Hills, Texas, 76180
Valley Clinical Trials, Inc.
Northridge, California, 91325
Advanced Research Institute
Ogden, Utah, 84405
Elite Clinical Studies, LLC
Phoenix, Arizona, 85018
Peace River Cardiovascular Center
Port Charlotte, Florida, 33952
Eastside Research Associates
Redmond, Washington, 98052
National Clinical Research, Inc
Richmond, Virginia, 23294
Rochester Clinical Research, LLC
Rochester, New York, 14609
Advanced Research Institute - Tigard
Tigard, Oregon, 97223
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098
Chase Medical Research, LLC
Waterbury, Connecticut, 06708
China12 sites
Beijing Pinggu District Hospital
Beijing, 101200
China-Japan Union Hospital
Changchun, 130033
Changde First People's Hospital
Changde, 415000
Sichuan Provincial People's Hospital
Chengdu, 610072
The Second Affiliated Hospital of Chongqing Medical University - Yuzhong Campus
Chongqing, 400010
Jinan Central Hospital
Jinan, 250013
Lishui Central Hospital
Lishui
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, 471003
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, 200001
Siping Central People's Hospital
Siping, 136000
Wuxi People's Hospital
Wuxi, 214023
Shaanxi provincial people's hospital
Xi'an, 710068
Argentina9 sites
Instituto Médico Especializado (IME)
Buenos Aires, 1405
CIPREC
Buenos Aires, C1061AAS
CIPREC
Buenos Aires, C1119ACN
CEMEDIC
Buenos Aires, C1407GTN
Instituto de Investigaciones Clínicas Córdoba
Córdoba, 5000
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, 2152
INECO Neurociencias Oroño
Rosario, 2000
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica
Rosario, 2000
Santa Maria de la Salud Centro Medico
San Isidro, 1642
Czechia9 sites
Top Moravia Health
Brno, 61500
Ordinace Rihackovi, s.r.o.
Brno, 641 00
CTC Hodonin s.r.o.
Hodonín, 695 01
MUDr. Sarka Drinkova
Ledeč nad Sázavou, 584 01
CCR Ostrava s.r.o
Ostrava, 702 00
Diahelp s.r.o
Pardubice V, 530 02
Clinoxus
Prague, 140 00
Angiocentrum Komorany
Prague, 143 00
Praglandia s.r.o
Prague, 150 00
Germany9 sites
Zentrum für klinische Studien Bad Homburg
Bad Homburg, 61348
FutureMeds GmbH
Berlin, 10629
Zentrum fur klinische Forschung - Köln
Cologne, 51069
Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien
Dresden, 01277
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, 01307
Medizentrum Essen Borbeck
Essen, 45355
AmBeNet GmbH
Leipzig, 04107
Familienmedizinisches Zentrum Radowsky
Leipzig, 04179
RED-Institut GmbH
Oldenburg, 23758
Poland8 sites
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, 15-276
Centrum Medyczne "Hipokrates" S.C. Elżbieta I Grzegorz Grześk
Bydgoszcz, 85-092
NZOZ Centrum Medyczne KERmed
Bydgoszcz, 85-231
IRMED
Piotrkow Trybunalski, 97-300
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu
Przemyśl, 37-700
Private Practice - Dr. Robert Witek
Tarnów, 33-100
Balsam Medica
Warsaw, 01-249
NZOZ Regionalna Poradnia Diabetologiczna
Wroclaw, 50-127
Spain7 sites
CHUAC-Complejo Hospitalario Universitario A Coruña
A Coruña, 15001
Hospital San Rafael - La Coruña
A Coruña, 15006
EAP Sardenya
Barcelona, 08025
EAP Osona Sud - Alt Congost S.L.P
Centelles, 08540
Complejo Asistencial Universitario de León - Hospital de León
León, 24071
Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
Seville, 41003
Hospital Quiron Infanta Luisa
Seville, 41010
Greece6 sites
Athens Medical Center - Psychikon branch
Athens, 115 25
General Hospital of Athens "G. Gennimatas"
Athens, 11527
University Hospital of Ioannina
Ioannina, 45500
G. Gennimatas General Hospital of Thessaloniki
Thessaloniki, 546 35
AHEPA University General Hospital of Thessaloniki
Thessaloniki, 546 36
Papageorgiou General Hospital of Thessaloniki
Thessaloniki, 56403
Japan5 sites
Tokyo-Eki Center-building Clinic
Chūōku, 103-0027
Fukuwa Clinic
Chūōku, 104-0031
Takai Internal Medicine Clinic
Kamakura-shi, 247-0056
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
Matsuyama, 7900034
Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
Yamato-shi, 242-0004
India4 sites
Life Care Hospital and Research Centre
Bangalore, 560092
All India Institute of Medical Sciences
Bhubaneswar, 751019
G.B. Pant Institute of Postgraduate Medical Education & Research
New Delhi, 110002
Ashirwad Hospital and Research Centre
Ulhasnagar, 421004
Puerto Rico2 sites
Dorado Medical Complex
Dorado, 00646
Puerto Rico Medical Research
Ponce, 00717
About this study
Official title: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
- Conditions
- Hypertension
- Being tested
- Orforglipron, Placebo
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OrforglipronDrug
Also called LY3502970
Administered orally
PlaceboDrug
placebo administered
| Study group | Role | What they receive |
|---|---|---|
| Orforglipron | Experimental | Participants will receive orforglipron orally. Receives: Drug: Orforglipron |
| Placebo | Placebo comparator | Participants receive placebo. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in office Systolic Blood Pressure (SBP)
Measured: Baseline to Week 36
Secondary outcomes (7)
Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP
Measured: Baseline to Week 36
Percent Change from Baseline in Body Weight
Measured: Baseline to Week 36
Percent Change from Baseline in Lipids Triglycerides
Measured: Baseline to Week 36
Percent Change from Baseline in Lipids non-HDL Cholesterol
Measured: Baseline to Week 36
Percent Change from Baseline in hsCRP Concentration (mg/L)
Measured: Baseline to Week 36
Percent Change from Baseline in office SBP in Randomized Withdrawal Population
Measured: Baseline to Week 36
Pharmacokinetics (PK): Steady-State Area under the Concentration Curve (AUC) of Orforglipron
Measured: Baseline to Week 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2025
- Study start30 Apr 2025
- Primary completionSep 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 487 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06952530
- Sponsor's protocol ID
- 27360
- Other IDs
- J2A-MC-GZL2, J2A-MC-GZPL
- Status last verified
- May 2026
- First submitted
- 21 Apr 2025
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
- ClinicalTrials.gov ID
- NCT06952530
- Acronym / sponsor ID
- 27360
- Conditions
- Hypertension
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 487 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 30 Apr 2025 (actual)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 1 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Orforglipron | Experimental | Drug: OrforglipronParticipants will receive orforglipron orally. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants receive placebo. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- refer to the GZPL master protocol study for screening eligibility.
Key exclusion criteria (1 listed)
- refer to the GZPL master protocol study for screening eligibility.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OrforglipronAlso: LY3502970Administered orally | Drug | Orforglipron |
| Placeboplacebo administered | Drug | Placebo |
Primary outcome
Change from Baseline in office Systolic Blood Pressure (SBP)
Time frame: Baseline to Week 36
7 secondary outcomes
Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP
Time frame: Baseline to Week 36
Percent Change from Baseline in Body Weight
Time frame: Baseline to Week 36
Percent Change from Baseline in Lipids Triglycerides
Time frame: Baseline to Week 36
Percent Change from Baseline in Lipids non-HDL Cholesterol
Time frame: Baseline to Week 36
Percent Change from Baseline in hsCRP Concentration (mg/L)
Time frame: Baseline to Week 36
Percent Change from Baseline in office SBP in Randomized Withdrawal Population
Time frame: Baseline to Week 36
Pharmacokinetics (PK): Steady-State Area under the Concentration Curve (AUC) of Orforglipron
Time frame: Baseline to Week 36
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
99 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Orforglipron in people with Hypertension, run by Eli Lilly and Company at 99 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 99 sites in United States, China, Argentina, Czechia, Germany and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in office Systolic Blood Pressure (SBP) (time frame: Baseline to Week 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.